ObjectiveTo observe the clinical effects of levosimendan injection combined with tolvaptan in the treatment of patients with acute heart failure (AHF) complicated with hyponatremia. MethodsA total of 98 AHF patients complicated with hyponatremia hospitalized in our hospital from January 2017 to January 2020 were selected as the research objects. They were divided into observation group and control group by the random number method, with 49 cases in each group. Patients in the control group were treated with levosimendan injection, whereas the observation group was treated with levosimendan injection combined with tolvaptan for treatment. After 7 days of treatment, the effective rate and 6-minute walking distance were compared between the two groups. The left ventricular ejection fraction (LVEF), stroke volume (SV), and cardiac index (CI), 24h urinary output, blood sodium levels of the two groups before and after 7 days of treatment were compared. The occurrence of adverse reactions between the two groups during the treatment was compared. ResultsAfter 7 days of treatment, patients in the observation group obtained a higher total effective rate (95.92% vs. 77.55%), and superior clinical efficacy as compared with the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of LVEF, SV, and CI between the two groups (P＞0.05). After 7 days of treatment, the levels of LVEF, SV, and CI of the two groups significantly increased, and the observation group yielded higher levels in comparison with the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in 24h urinary output and blood sodium level between the two groups (P＞0.05). After 7 days of treatment, the 24h urinary output and blood sodium level of the two groups significantly increased, and the observation group yielded higher levels in comparison with the control group, and the 6-minute walking distance of the observation group was significantly longer than that of the control group, with statistically significant differences (P＜0.05). During the course of treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionLevosimendan injection combined with tolvaptan can effectively alleviate the clinical symptoms of patients with AHF complicated with hyponatremia, improve heart function, increase urinary output and blood sodium level, enhance exercise tolerance, and thus it is highly safe for treatment.

无